TORONTO, May 7 /CNW/ - Patheon Inc. (TSX: PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, today confirmed that it has received a requisition for a special
meeting of shareholders signed by Mr. Joaquin Viso and Ms. Olga Lizardi to
remove from office each of the six directors of Patheon that were elected by
holders of Patheon's restricted voting shares at Patheon's annual meeting of
shareholders held on April 29, 2009 and to replace those directors with
nominees to be proposed at or before the requisitioned meeting of
shareholders. According to a news release issued by Mr. Viso, it is proposed
that the replacement nominees would include Mr. Wesley Wheeler, Patheon's
President and Chief Executive Officer, and Mr. Viso. Patheon is reviewing the
requisition and will announce its response in due course.
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email: email@example.com; Ms. Doaa A.
Fathallah, Senior Vice President, General Counsel - Europe, Global PDS &
Corporate Secretary, Tel: +41 79 404 3085, Email: firstname.lastname@example.org